Thyroid Eye Disease (TED) Global Market Report 2025

The thyroid eye disease (TED) market size has grown strongly in recent years. It will grow from $2.15 billion in 2024 to $2.3 billion in 2025 at a compound annual growth rate (CAGR) of 7%. The growth during the historic period can be attributed to the rising incidence of thyroid disorders, a growing emphasis on patient-centered care, increasing demand for cosmetic procedures, a higher prevalence of the disease, and the expansion of treatment options for TED.

The thyroid eye disease (TED) market size is expected to see strong growth in the next few years. It will grow to $2.97 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth during the forecast period can be driven by the rising prevalence of Graves' disease, increased funding across various industries, growing healthcare expenditure, greater use of thyroid hormone replacement therapy, and a higher incidence of thyroid disease. Key trends in this period include technological advancements, expanding R&D activities, the development of novel drugs, improvements in treatment options, and the introduction of new surgical techniques.

The increasing prevalence of thyroid disorders is expected to drive the expansion of the thyroid eye disease (TED) market. Thyroid disorders are medical conditions that disrupt the function of the thyroid gland, leading to hormonal imbalances and conditions such as hypothyroidism, hyperthyroidism, goiter, and thyroid eye disease. The rising incidence of thyroid disorders is attributed to factors such as increased iodine intake, autoimmune diseases, genetic predisposition, and improved awareness leading to higher diagnostic rates. Thyroid Eye Disease (TED) plays a significant role in the growing number of thyroid disorder cases, as it is a serious and common complication of Graves' disease, contributing to the overall burden and awareness of thyroid-related conditions. For example, in May 2024, the Canadian Cancer Society, a Canada-based non-profit organization, reported that an estimated 6,600 new cases of thyroid cancer are expected to be diagnosed in Canada in 2024, with approximately 280 projected fatalities. As a result, the increasing prevalence of thyroid disorders is fueling the growth of the thyroid eye disease (TED) market.

Leading companies in the thyroid eye disease (TED) market are prioritizing the development of innovative treatments, such as monoclonal antibody therapies, to provide more effective, targeted solutions that reduce inflammation, improve proptosis, and enhance overall patient outcomes. Monoclonal antibody therapies involve laboratory-engineered antibodies designed to mimic the immune system’s ability to recognize and neutralize specific pathogens or abnormal cells. For instance, in September 2024, Amgen Inc., a US-based biotechnology company, announced that Japan's Ministry of Health, Labour and Welfare (MHLW) had approved TEPEZZA (teprotumumab) for the treatment of active thyroid eye disease (TED), a rare and potentially vision-threatening autoimmune disorder. TEPEZZA is the first and only FDA-approved therapy specifically for TED, offering a targeted treatment that helps reduce inflammation, swelling, and other debilitating symptoms associated with the disease. This approval is particularly significant for patients in Japan, as it introduces an effective new option for managing TED, a progressive condition that can cause severe eye bulging, vision impairment, and eye pain.

In October 2023, Amgen Inc., a US-based biopharmaceutical company, acquired Horizon Therapeutics plc for an undisclosed amount. This acquisition strengthens Amgen’s rare and inflammatory disease portfolio by integrating Horizon’s key therapies, expanding its global reach, and driving innovation for long-term growth. Horizon Therapeutics plc, an Ireland-based company, specializes in treatments for rare autoimmune and inflammatory diseases.

Major players in the thyroid eye disease (ted) market are Hoffmann-La Roche AG, Amgen Inc., Genentech Inc., Horizon Therapeutics plc, Pierre Fabre S.A., Innovent Biologics Inc., ACELYRIN Inc., Soleo Health, Zai Lab Limited, HanAll Biopharma Co. Ltd., Tourmaline Bio Inc., Zenas BioPharma Inc., Immunovant Inc., Verana Health, Harbour BioMed (Guangzhou) Co. Ltd., Sling Therapeutics Inc., Crinetics Pharmaceuticals Inc., Lassen Therapeutics Inc., Viridian Therapeutics Inc., Minghui Pharmaceutical Inc.

North America was the largest region in the thyroid eye disease (TED) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in thyroid eye disease (TED) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the thyroid eye disease (TED) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Thyroid eye disease (TED), also known as Graves' Orbitopathy, is an autoimmune disorder marked by inflammation and swelling of the tissues surrounding the eyes, often linked to thyroid conditions. TED can lead to symptoms such as bulging eyes, double vision, and eye discomfort.

The primary treatment approaches for TED include medical, surgical, and a combination of both. Medical management typically involves corticosteroids, immunosuppressive drugs, and biologic therapies to reduce inflammation, alleviate symptoms, and prevent disease progression. Treatment is customized based on disease severity, classified into mild, moderate, and severe stages. The drugs used belong to various categories, including biologics, small molecules, and others. They are administered through different routes, such as oral, intravenous, and subcutaneous methods, and are utilized by various end users, including hospitals, clinics, and other healthcare facilities.

The thyroid eye disease (TED) market research report is one of a series of new reports that provides thyroid eye disease (TED) market statistics, including the thyroid eye disease (TED) industry global market size, regional shares, competitors with the thyroid eye disease (TED) market share, detailed thyroid eye disease (TED) market segments, market trends, and opportunities, and any further data you may need to thrive in the thyroid eye disease (TED) industry. This thyroid eye disease (TED) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The thyroid eye disease (TED) market includes revenues earned by entities by providing services such as diagnosis services, pharmaceutical services, surgical services, support, and counseling services and related products including thyroid hormone replacement therapy, immunosuppressive drugs, surgical products, and devices. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.